Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829808 | 0.85 | GABBR2 (0.40) | DRD1CA2GABRA1GABRB2TDP1 | |
| SCHEMBL24272577 | 0.81 | DRD1 (0.33) | DRD1CA2GABBR2GABBR1 | |
| SCHEMBL21222728 | 0.74 | ALDH1A1 (0.53) | CA2ALDH1A1ALOX5PTGS1PTGS2 | |
| SCHEMBL15580435 | 0.74 | CA2 (0.46) | CA2GABRA1GABRB2TDP1ALDH1A1 | |
| SCHEMBL11910663 | 0.72 | DRD1 (0.50) | DRD1CA2TDP1ALDH1A1TSHR | |
| SCHEMBL29589463 | 0.72 | DRD1 (0.58) | DRD1 | |
| SCHEMBL20594109 | 0.72 | DRD1 (0.42) | DRD1 | |
| SCHEMBL1315091 | 0.72 | DRD1 (0.58) | DRD1 | |
| SCHEMBL29883736 | 0.72 | DRD1 (0.58) | DRD1 | |
| SCHEMBL2692662 | 0.72 | PTGS2 (0.54) | ALOX5PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906669-B2 | Metallocene-based phosphorus chiral phosphines | SOLVIAS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| US-20090137824-A1 | METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES | PHOENIX CHEMICALS LTD (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20080242876-A1 | Process For the Manufacture of Substituted Propionic Acids | PHOENIX CHEMICALS LTD. (GB) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137824-A1 | METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES | POLL, ZNF207, ZC3HAV1L | DRD1 1187/4885CA2 1538/4885GABRA1 2538/4885 |
| US-20080242876-A1 | Process For the Manufacture of Substituted Propionic Acids | AS3MT, PPA1, AGPS | DRD1 3828/4885CA2 31/4885GABRA1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.